SPRY Stock Summary and Trading Ideas (Ars Pharmaceuticals | NASDAQ:SPRY)

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Ars Pharmaceuticals trades on the NASDAQ stock market under the symbol SPRY.

As of February 26, 2026, SPRY stock price climbed to $9.25 with 480,744 million shares trading.

SPRY has a beta of 0.29, meaning it tends to be less sensitive to market movements. SPRY has a correlation of 0.01 to the broad based SPY ETF.

SPRY has a market cap of $914.14 million. This is considered a Small Cap stock.

Last quarter Ars Pharmaceuticals reported $33 million in Revenue and -$.52 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.05.

In the last 3 years, SPRY traded as high as $18.90 and as low as $2.55.

The top ETF exchange traded funds that SPRY belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

SPRY has underperformed the market in the last year with a price return of -12.4% while the SPY ETF gained +16.5%. SPRY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -0.3% and -2.6%, respectively, while the SPY returned +1.8% and -1.0%, respectively.

SPRY support price is $8.90 and resistance is $9.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRY shares will trade within this expected range on the day.